Pefloxacin

Pefloxacin

SCHEMBL34292

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrBparCparE

The experimentally established mechanism targets of Pefloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 1.00
MEN1 O00255 8/20 0.90
KMT2A Q03164 8/20 0.90
KDM4E B2RXH2 7/20 0.90
ALDH1A1 P00352 5/20 0.90
HPGD P15428 3/20 0.90
NPC1 O15118 1/20 0.90
HSD17B10 Q99714 3/20 0.79
GAA P10253 1/20 0.79
RAD52 P43351 1/20 0.79
LMNA P02545 2/20 0.78
TSHR P16473 2/20 0.78
HTT P42858 2/20 0.78
BRD4 O60885 1/20 0.78
CYP2J2 P51589 1/20 0.78
NPSR1 Q6W5P4 1/20 0.78
GLA P06280 1/20 0.72
HIF1A Q16665 1/20 0.71
USP2 O75604 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pefloxacin SCHEMBL29351730 1.00 DRD3 (1.00) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL28251251 1.00 DRD3 (1.00) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL7861481 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL9788090 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL9800276 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL10911017 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL8184732 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL28542234 0.99 DRD3 (0.98) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL29594648 0.95 KDM4E (1.00) DRD3MEN1KMT2AKDM4EALDH1A1
Pefloxacin SCHEMBL135085 0.95 KDM4E (1.00) DRD3MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 13245 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122042636-A Quick qualitative and quantitative analysis method for quinolone antibiotics in soil 中国科学院城市环境研究所 2026-05-15 CN claimed
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4434588-B1 AEROSOL DELIVERY DEVICE PARI PHARMA GMBH (DE) 2026-04-08 EP claimed
US-20260090584-A1 SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION SCIENTIFIC HORIZONS CONSULTING LLC (US) 2026-04-02 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4659014-A1 EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING President And Fellows Of Harvard College (US) 2025-12-10 EP claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-0255926-A2 Antibacterial adhesive sheet and method for making it HOECHST AKTIENGESELLSCHAFT (DE) 1988-02-17 EP claimed
EP-0228592-A2 Bone cement GMT Gesellschaft für medizinische Technik mbH (DE) 1987-07-15 EP claimed
EP-0222814-A1 USE OF QUINOLONE DERIVATIVES FOR THE TREATMENT OF MYCOPLASMAL PNEUMONIA IN PIGS BEECHAM GROUP PLC (GB) 1987-05-27 EP claimed
EP-0207624-A2 Method for preparing infection-resistant materials The Trustees of Columbia University in the City of New York (US) 1987-01-07 EP claimed
WO-1986006630-A1 USE OF QUINOLONE DERIVATIVES FOR THE TREATMENT OF MYCOPLASMAL PNEUMONIA IN PIGS BEECHAM GROUP P.L.C. (GB) 1986-11-20 WO claimed
US-4612337-A SOAKING POLYMERIC MATERIAL WITH MICROBIOCIDE AND SOLVENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1986-09-16 US claimed
US-4563485-A SURGICAL IMPLANTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1986-01-07 US claimed
US-4551456-A BACTERICIDES MERCK & CO., INC. (US) 1985-11-05 US claimed
EP-0142426-A2 Ophthalmic formulation containing norfloxacin and related antibiotics MERCK & CO. INC. (US) 1985-05-22 EP claimed
US-4292317-A BACTERICIDES FOR GRAM NEGATIVE AND -POSITIVE BACTERIA; ANIMAL GROWTH REGULATORS LABORATORIE ROGER BELLON (FR) 1981-09-29 US claimed